EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers

Konstantinos Kapriniotis, Ioannis Loufopoulos, Mohammad U Sharif iD, Ioannis Manolitsis iD, Lazaros Tzelves iD, Amy Nagle, James S A Green

Journal of Personalized Medicine · 16.04.2026 · 16 (4) · 220

DOI: 10.3390/jpm16040220 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 16.04.2026. Verfasst von Konstantinos Kapriniotis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Whipps Cross University Hospital, London E11 1NR, UK. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Upper tract urothelial carcinoma is a rare disease with variable prognosis depending on the stage and grade at diagnosis. Current modalities are far from perfect in diagnosis and risk stratification. In this setting, there is an urgent need for diagnostic and prognostic biomarkers to overcome these limitations.

Methods

We carried out a narrative review of the literature searching for research articles on diagnostic and prognostic biomarkers for upper tract urothelial carcinoma (UC) and underlined the limitations of current diagnostic modalities.

Results

CT urogram (CTU) is the imaging modality of choice in suspected upper tract UC with sensitivity and specificity exceeding 90% but with limitations in smaller lesions. Urine cytology has an excellent specificity for high-grade UC but is limited by low sensitivity leading to a high number of diagnostic ureteroscopies with significant associated risks. Adjuncts such as Fluorescence In Situ Hybridization (FISH) technology and urine DNA methylation markers have shown promising results but need further validation in large cohorts of upper tract UC. Finally, circulation tumour DNA (ctDNA) is a novel approach with great potential in risk stratification and monitoring of minimal residual disease post radical surgery; however, larger prospective studies are required to validate its role similarly to the recent bladder UC trials.

Conclusions

There is an urgent need for non-invasive biomarkers that can reliably replace diagnostic ureteroscopies, identify high-risk/invasive disease and select patients for radical surgery or kidney sparing procedures.

Schlagwörter

Stichwörter der Autor:innen

biomarkersdiagnosisprognosisupper tracturothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology, Whipps Cross University Hospital, London E11 1NR, UK.
  • Department of Urology, Royal Free Hospital, London NW3 2QG, UK.
  • Department of Urology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
  • 2nd Department of Urology, National and Kapodistrian University of Athens, 151 26 Athens, Greece.

ORCID-Profile: Mohammad U Sharif, Ioannis Manolitsis, Lazaros Tzelves

Zitieren

APA

Kapriniotis, K., Loufopoulos, I., Sharif, M. U., Manolitsis, I., Tzelves, L., Nagle, A., & Green, J. S. A. (2026). Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers. Journal of Personalized Medicine, 16(4), 220. https://doi.org/10.3390/jpm16040220

Vancouver

Kapriniotis K, Loufopoulos I, Sharif MU, Manolitsis I, Tzelves L, Nagle A, et al. Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers. Journal of Personalized Medicine. 2026;16(4):220. doi:10.3390/jpm16040220

BibTeX
@article{Kapriniotis2026,
  author = {Kapriniotis, Konstantinos and Loufopoulos, Ioannis and Sharif, Mohammad U and Manolitsis, Ioannis and Tzelves, Lazaros and Nagle, Amy and Green, James S A},
  title = {Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers},
  journal = {Journal of Personalized Medicine},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {220},
  doi = {10.3390/jpm16040220}
}
Kostenlos starten →